Situated at Chiplun
Lasa Supergenerics has commenced the trial production at Unit IV, situated at Chiplun. The planned production and capacity per annum includes Albendazole Intermediate (400 MT), Fenbendazole Intermediate (200 MT), 2 4 DCP (600 MT), Closantel Intermediate (100 MT) and additionally a few components of backward integration for its recent new launches.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
